Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record.

Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial

Lansky, Alexandra J., Pietras, Cody, Costa, Ricardo A., Tsuchiya, Yoshihiro, Brodie, Bruce R., Cox, David A., Aymong, Eve D., Stuckey, Thomas D., Garcia, Eulogio, Tcheng, James E., Mehran, Roxana, Negoita, Manuela, Fahy, Martin, Cristea, Ecaterina, Turco, Mark, Leon, Martin B., Grines, Cindy L., Stone, Gregg W. · 2005 · Circulation

Abstract

Background— Women with acute myocardial infarction (AMI) undergoing primary angioplasty have higher rates of morbidity and mortality than do men. Whether contemporary interventional treatment strategies have improved outcomes for women compared with men is unknown. Methods and Results— In the CADILLAC trial, 2082 patients (27% women) with AMI within 12 hours of symptom onset were randomized to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528), stenting (n=512), and stenting+abciximab (n=524). As compared with men, women had a lower body surface area; had a greater prevalence of diabetes, hypertension, and hyperlipidemia; experienced significant delays to treatment; and had better baseline and final TIMI grade 3 flows. Unadjusted 1-year event rates were higher for women, including death (7.6% versus 3.0%, P <0.001), ischemic target-vessel revascularization (TVR; 16.7% versus 12.1%, P =0.006), and major adverse cardiac events (MACE; 23.9% versus 15.3%, P <0.001). Female gender was an independent predictor of MACE and bleeding complications, although comorbid risk factors and body surface area but not gender predicted 1-year death. For women, primary stenting resulted in a reduction in 1-year MACE from 28.1% to 19.1% ( P =0.01) and in ischemic TVR from 20.4% to 10.8% ( P =0.002) compared with PTCA. The addition of abciximab to primary stenting significantly reduced the 30-day ischemic TVR without increasing bleeding or stroke rates. Conclusions— The higher mortality rate in women compared with men after interventional treatment for AMI may be explained by differences in body size and clinical risk factors, although female gender remains an important independent determinant of overall adverse outcomes. For women in the CADILLAC trial, the addition of abciximab reduced 30-day TVR without increasing bleeding risk, and primary stenting reduced 1-year TVR and MACE rates compared with PTCA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000160362.55803.40

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 191

Metadata

Authors
Lansky, A. J., Pietras, C., Costa, R. A., Tsuchiya, Y., Brodie, B. R., Cox, D. A., Aymong, E. D., Stuckey, T. D., Garcia, E., Tcheng, J. E., Mehran, R., Negoita, M., Fahy, M., Cristea, E., Turco, M., Leon, M. B., Grines, C. L., & Stone, G. W.
Venue
Circulation
Published
2005-04-05
Volume
111
Issue
13
Pages
1611-1618
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2103765008
Cited by
191
References
0
FWCI
10.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. https://app.cochat.ai/papers/10.1161/01.cir.0000160362.55803.40
The paper
Lansky, A. J., Pietras, C., Costa, R. A., Tsuchiya, Y., Brodie, B. R., Cox, D. A., Aymong, E. D., Stuckey, T. D., Garcia, E., Tcheng, J. E., Mehran, R., Negoita, M., Fahy, M., Cristea, E., Turco, M., Leon, M. B., Grines, C. L., & Stone, G. W. (2005). Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Circulation. https://doi.org/10.1161/01.cir.0000160362.55803.40

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.